- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
- Interventions
- Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel
- Drug
- Lead sponsor
- ALX Oncology Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Anaheim, California • Los Angeles, California • Nashville, Tennessee + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 2,451
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
- Interventions
- Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration, Quality-of-life assessment, Placebo Administration
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 33
- States / cities
- Irvine, California • Orange, California • Clearwater, Florida + 26 more
- Conditions
- Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- vorinostat, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Solid Tumor, Adult
- Interventions
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
- Combination Product
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
- Conditions
- Breast Neoplasm, Neoplasm Metastasis
- Interventions
- Monoclonal Antibody 3A1, Monoclonal Antibody 95-5-49, Monoclonal Antibody 95-6-22, Baxter Isolex 3001 Stem Cell Selection System, Ceprate SC
- Drug · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer
- Interventions
- Trametinib (GSK1120212), Docetaxel, Erlotinib, Pemetrexed, Carboplatin, nab-Paclitaxel, Cisplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Duarte, California • Sacramento, California + 10 more
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Paclitaxel
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Miami, Florida • Chicago, Illinois • Zion, Illinois + 1 more
- Conditions
- Chronic Limb-Threatening Ischemia
- Interventions
- PCB, PTA
- Device
- Lead sponsor
- Acotec Scientific Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 16
- States / cities
- Concord, California • Fremont, California • New Haven, Connecticut + 12 more
- Conditions
- Pancreatic Cancer
- Interventions
- Demcizumab, Abraxane®, gemcitabine, Placebo
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 22
- States / cities
- Gilbert, Arizona • Burbank, California • Duarte, California + 19 more
- Conditions
- Recurrent Ovarian Cancer
- Interventions
- ChemoID assay, Chemotherapy
- Diagnostic Test · Drug
- Lead sponsor
- Cordgenics, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Jackson, Mississippi • Charleston, West Virginia • Huntington, West Virginia
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
- Interventions
- azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- pertuzumab in combination with trastuzumab and paclitaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Gastrointestinal Neoplasm
- Interventions
- Cytoreductive surgery, Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- Sorafenib, Cisplatin, Paclitaxel
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Early Breast Cancer
- Interventions
- Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
- Conditions
- Coronary Artery Disease
- Interventions
- TAXUS Liberté Paclitaxel-Eluting Coronary Stent, prasugrel, placebo, aspirin
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 82
- States / cities
- Mesa, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 72 more
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
- Interventions
- paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
- Drug · Radiation · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Estramustine, Thalidomide, Paclitaxel (Taxol)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Stage III Ovarian Cancer, FIGO Stage IIIA Ovarian Cancer, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA1(i) Ovarian Cancer, FIGO Stage IIIA1(ii) Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer, FIGO Stage IIIC Ovarian Cancer, FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Bevacizumab, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 5
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
- Conditions
- Lung Cancer
- Interventions
- paclitaxel albumin-stabilized nanoparticle formulation
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer
- Interventions
- Vaginal Cuff Brachytherapy
- Radiation
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
- Interventions
- Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- ombrabulin (AVE8062), placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 2 more